In 2013, the Isacke group determined that RET signaling is hyperactivated in aromatase-resistant ER+ breast cancer and that pharmacological RET inhibition impairs GDNF-mediated aromatase inhibitor resistance (152). This evidence concerns the gene CYP19A1 and breast carcinoma.